Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
Medical University of South Carolina
Mayo Clinic
Gustave Roussy, Cancer Campus, Grand Paris
Massachusetts General Hospital
The Second Affiliated Hospital of Fujian Medical University
University of Washington
Fred Hutchinson Cancer Center
University of Rochester
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
Medical College of Wisconsin
Mayo Clinic
City of Hope Medical Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
University of Maryland, Baltimore
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Roswell Park Cancer Institute
Mayo Clinic
Chinese PLA General Hospital
Peking University Cancer Hospital & Institute
Stanford University
University of Chicago
University of Kansas Medical Center
Stanford University
Affiliated Hospital to Academy of Military Medical Sciences
Uppsala University
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Peking University Cancer Hospital & Institute
Sunnybrook Health Sciences Centre
Masonic Cancer Center, University of Minnesota
The First Affiliated Hospital of Soochow University
Chongqing University Cancer Hospital
Shanghai Pudong Hospital
The First Affiliated Hospital of Soochow University
Zhejiang University
Northwestern University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
First Affiliated Hospital of Wenzhou Medical University
Xinqiao Hospital of Chongqing
Oncology Specialists, S.C.
Stanford University
Masonic Cancer Center, University of Minnesota
Peking University
Duke University
Shenzhen Second People's Hospital